MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • SciClone Pharmaceuticals (SCLN) Continues Growth in China 0 comments
    Oct 27, 2011 1:51 PM | about stocks: SCLN

    SciClone Pharmaceuticals is a China-centric specialty pharmaceutical company focused on therapies for oncology and infectious diseases, along with cardiovascular, urological, respiratory, and central nervous system disorders. The company was founded in 1989 and is headquartered south of San Francisco in Foster City, California.


    SciClone’s flagship product, ZADAXIN® (thymalfasin), is approved in over 30 countries for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and for certain cancers. The product has seen steady growth since its introduction to China in the mid-1990s. Besides ZADAXIN, the company markets about 20 products in China, mostly through partnerships, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China, Tritace®, an ACE inhibitor for the treatment of hypertension, Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US), and Aggrastat®, a recently-launched intervention cardiology product.


    SciClone also has a strong pipeline of product candidates, 10 of which are in clinical trials or in other stages of regulatory approval in China. On the development side, SciClone is evaluating SCV-07 in a phase 2b trial to modify the course of oral mucositis in patients with head and neck cancer.


    The company’s April, 2011, acquisition of NovaMed Pharmaceuticals, a China based pharmaceutical company, represented a significant near-term boost in revenues, strengthening SciClone’s balance sheet and their overall position in China.


    SciClone’s growth over the years can be traced to a history of talented leadership from people who have gone on to play key roles in the industry, such as Shawn Singh who served in many key positions in the early development of SciClone. Mr. Singh is currently the CEO of VistaGen Therapeutics (OTCBB: VSTA), a California biotechnology company primiarly focused on using proprietary stem cell technologies for drug rescue and cell therapy. SciClone’s current President and CEO is Friedhelm Blobel, Ph.D., who has had an extensive pharmaceutical career supporting operations in the U.S. and Asia.


    For additional information, visit the company’s website at SciClone.com



    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: SCLN
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.